GC117 I Want To Have A Baby Male And Female Infertility

Male and female infertility refers to the inability of a couple to achieve pregnancy after 12 months of regular unprotected intercourse, resulting from disorders of sperm production or function, ovulatory dysfunction, tubal damage, uterine abnormalities, or unexplained factors in either partner.

I Want to Have a Baby: Male and Female Infertility

This lecture, delivered by Professor Ernest Hung Yu NG (Department of O&G, HKU), is a cornerstone General Clerkship session on reproductive medicine. It covers the entire clinical pathway from understanding normal fertility, through identifying causes of infertility in both sexes, to systematic investigation and evidence-based treatment including assisted reproductive technologies (ART). The lecture directly maps to summative exam questions on definitions, investigation thresholds, ovulation induction pharmacology, IVF procedures, and ethical dimensions of fertility treatment.

Learning Objectives [1][2]:

  1. Understand normal fertility (sperm journey, ovulation, fertilization, implantation)
  2. Know the causes of infertility (male, female, unexplained)
  3. Systematic investigations for infertility
  4. Treatment options including medical, surgical, and ART

Why this matters clinically: Infertility affects 10–15% of couples. A GP or O&G clinician must be able to take a focused history, start parallel assessment of both partners, assess ovulatory status, arrange semen analysis and select a tubal-patency test when indicated. Serum progesterone and laparoscopy are not automatic tests for everyone. Understanding the principles of IVF/ICSI is essential for counselling [13][20].



1. Normal Fertility

Millions of sperm at coitus → about 1% reach the endocervical canal → only a few thousand reach the Fallopian tube [1]

How to read the journey diagram: Attrition occurs at the vagina, cervix and uterotubal junction; fertilization normally occurs in the tubal ampulla. The diagram explains why semen parameters matter, but it does not create a sharp fertile/infertile cut-off—fertile and infertile populations overlap substantially.

Normal fertility in women involves follicle development → ovulation → fertilization in the Fallopian tube → embryo implantation in the endometrium [1]

  • Follicular phase: FSH recruits a cohort of follicles; one becomes dominant, producing rising oestradiol
  • Ovulation: LH surge triggers follicular rupture ~36 hours later
  • Luteal phase: Corpus luteum produces progesterone, preparing the endometrium
  • Fertilization window: Oocyte viable ~12–24 hours; sperm viable ~3–5 days → fertile window is approximately 6 days ending on the day of ovulation

How to read the cycle diagram: FSH supports follicular growth and rising oestradiol during the proliferative phase. Sustained oestradiol produces the mid-cycle LH surge; follicular rupture follows, and the corpus luteum then secretes progesterone, converting the endometrium to a secretory pattern and raising basal body temperature. After fertilization in the tube, cleavage occurs during transit; the blastocyst reaches the uterine cavity for implantation.

Peak monthly pregnancy rate ~25–30%; cumulative rate at 1 year ~80%; at 2 years ~90% [1]

High Yield - Pregnancy Rates

These numbers are crucial for interpreting ART success rates. If natural conception gives 80% at 1 year, then any ART must be compared against this baseline. A treatment giving 30% per cycle sounds impressive until you realize natural rates are 25–30%/month. This is why "cumulative pregnancy rate" matters more than per-cycle rates.


Definition 1: A disease characterized by failure to establish a clinical pregnancy after 12 months of regular unprotected sexual intercourse (International Glossary 2017) [1]

Definition 2: Failure to achieve pregnancy within 12 months in women < 35 years OR within 6 months in women > 35 years (ACOG/ASRM 2019) [1]

Current threshold: Begin evaluation after 12 months if the female partner is under 35 and after 6 months at age 35 or older; consider immediate evaluation above 40 or whenever history identifies a known infertility risk [13].

10–15% of couples affected [1]

Why the age distinction? Ovarian reserve declines steeply after age 35. Fecundability (monthly probability of conception) drops from ~25% at age 25 to ~10% at age 40. Waiting 12 months in a 38-year-old wastes precious reproductive time, so the threshold for investigation is halved to 6 months.


Both women and men can be affected. Multiple factors are common. [1]

CategoryApproximate %Examples
Male factors30%Production defects (idiopathic, endocrine, trauma, genetic); obstructive (absent vas, vasectomy); coital problems
Ovulatory dysfunction15%PCOS, hypothalamic amenorrhoea, hyperprolactinaemia, ovarian insufficiency
Tubal factors20%PID, endometriosis, previous surgery, ectopic
Endometriosis25%Distorted anatomy, inflammatory peritoneal environment
Cervical/immunological/coitalUncommonAntisperm antibodies, vaginismus
UnexplainedBy exclusionOvulation confirmed + patent tubes + normal semen

Exam Framing - Five Important Causes

The five important causes per the lecture: (1) Ovulatory dysfunction/anovulation, (2) Tubal problems, (3) Endometriosis, (4) Male factors, (5) Unexplained [1]. This is the framework examiners expect you to use when listing causes.


4. History and Examination

Female: Age, menstrual cycle regularity (21–35 days), history of pelvic infection or surgery, previous investigations and treatment [1]

Male: Age/occupation, past health, coital history, smoking/alcohol [1]

Why each element matters:

  • Age of the woman is the single most important prognostic factor (declining oocyte quality and quantity)
  • Menstrual regularity (21–35 days) suggests 95% chance of ovulation [1] — this is a key teaching point
  • Pelvic infection/surgery → tubal damage risk
  • Coital history → frequency, timing, erectile dysfunction (a commonly overlooked cause)
  • Smoking → reduces ovarian reserve in women, impairs sperm quality in men
  • Occupation (male) → exposure to heat, chemicals, radiation

Female: Body weight, vaginal examination (uterine size, mobility, adnexal mass) [1]

Male: Testicular size, vas and epididymis, varicocele (? Necessary = the slide questions whether male exam is always needed) [1]

Why body weight? Obesity causes anovulation via excess peripheral oestrogen conversion (aromatase in adipose tissue) and insulin resistance → hyperandrogenism. BMI > 30 significantly reduces IVF success. Conversely, BMI < 18.5 causes hypothalamic amenorrhoea.

Female: > 35 years old, irregular cycles, previous pelvic surgery, previous STD, abnormal pelvic examination [1]

Male: Systemic illness, previous genital pathology, previous STD, varicocele, abnormal genital examination [1]

Note: The lecture slide lists systemic illness under male early referral criteria [1].

For current practice, read the slide's “> 35” as age 35 or older, and do not wait for a time threshold when there is a known condition associated with infertility [13].


5. Investigations

5.1 Semen Analysis

The slide-era approach was 2–3 samples after 2–7 days of sexual abstinence. Current evaluation begins with one or more WHO-standard semen analyses; an abnormal first test should be repeated. [1][14][20]

Why repeat an abnormal sample? Semen parameters vary considerably between ejaculates. NICE recommends a confirmatory sample, ideally after about 3 months to cover a spermatogenic cycle, but sooner for azoospermia or severe oligozoospermia; AUA/ASRM notes that at least two samples, ideally at least 1 month apart, are especially important when the first is abnormal [14][20].

Why 2–7 days abstinence? Too short (under 2 days) → low volume and count. Too long (over 7 days) → increased proportion of dead/immotile sperm and decreased motility.

Reference group: fertile men whose partners (regular cycles, bilateral patent tubes) got pregnant within 12 months. 5th centile used as lower reference values. [1]

Parameter5th Edition6th Edition
Semen volume (mL)1.51.4
Concentration (×10⁶/mL)1516
Total sperm number (×10⁶)3939
Total motility (%)4042
Progressive motility (%)3230
Morphology (%)44

Critical Exam Point - Semen Analysis Overlap

Extensive overlap exists between fertile and infertile men. None of the semen parameters is diagnostic of infertility. [1] The study by Guzick et al. (NEJM 2001) showed: Fertile men had mean concentration 67±50 vs infertile 52±42; motility 54±13 vs 49±15; morphology 14±5 vs 11±6. The distributions overlap massively. This means a man with "abnormal" WHO values may still be fertile, and vice versa. Semen analysis is a screening test, not a diagnostic test.

No absolute concentration cut-off for natural conception: In the testosterone male-contraception data shown on the slide, pregnancies still occurred with concentrations in the 0.1–3 million/mL range [1]. The 3 million/mL figure was a contraceptive-efficacy target, not a sterility threshold. Apart from confirmed azoospermia and a few complete functional defects, no single semen parameter proves infertility [14].

TermDefinition
OligozoospermiaSperm concentration < 16M/mL (6th ed)
AsthenozoospermiaTotal motility < 42%
TeratozoospermiaNormal morphology < 4%
AzoospermiaNo sperm in ejaculate
Oligoasthenoteratozoospermia (OAT)All three abnormal

5.2 Causes of Male Infertility

Three categories: (1) Disorders of testicular control, (2) Obstructive disorders, (3) Primary testicular disorders [1]

CategoryCausesKey Details
Disorders of testicular controlHypogonadotrophic hypogonadism, HyperprolactinaemiaLow FSH/LH → low testosterone → impaired spermatogenesis. Treatable with gonadotrophins or GnRH pulsatile therapy
Obstructive disordersInfections, Congenital absence of vas deferens (CBAVD), VasectomyCBAVD associated with CF carrier status (CFTR mutations) [5]. Normal FSH, normal testicular size, azoospermia
Primary testicular disordersKlinefelter syndrome (47,XXY), Varicocele, Infections (mumps), Trauma, Cryptorchidism, Radiotherapy/chemotherapy, Chronic illnessKlinefelter's: small firm testes, tall stature, gynaecomastia, azoospermia, elevated FSH [3][6]

Y chromosome microdeletions: 3 deletion regions (AZFa, AZFb, AZFc) on Yq11 linked with male infertility. Different regions affect distinct phases of spermatogenesis. No sperms found in AZFa and AZFb deletions. [1]

Clinical significance:

  • AZFa deletion → Sertoli cell-only syndrome → complete absence of germ cells → azoospermia → NO sperm retrieval possible
  • AZFb deletion → maturation arrest → azoospermia → NO sperm retrieval possible
  • AZFc deletion → variable phenotype, some sperm may be found → TESE may retrieve sperm for ICSI

Y chromosome microdeletion markers (lecture slide) [1]:

Deletion RegionMarkers
AZFasY84, sY86
AZFbsY127, sY131
AZFcsY254, sY255

These sequence-tagged site (STS) markers are used in PCR-based screening for Y microdeletions in men with severe oligozoospermia or azoospermia.

Exam Trap

If asked about prognosis of Y microdeletion, remember that AZFa and AZFb deletions have the worst prognosis (no sperm retrieval possible), while AZFc may still allow sperm extraction. Also, if ICSI is used with AZFc sperm, male offspring will inherit the deletion and be infertile too — important for genetic counselling.

The lecture listed FSH/prolactin/testosterone, karyotype/Y-microdeletion testing, vasography and selective biopsy. These are directed—not blanket—tests. [1]

Current selection principles [14]:

  • Obtain FSH and testosterone when there is oligozoospermia/azoospermia, impaired libido or erectile function, atrophic testes, or other evidence of hormonal abnormality; add LH when testosterone is low and prolactin when hypogonadotropic features or reduced libido suggest it.
  • Use examination, semen volume and FSH to distinguish obstruction from impaired production. Routine diagnostic testicular biopsy and routine scrotal/TRUS imaging are not recommended; TRUS is reserved for a semen pattern suggesting ejaculatory-duct obstruction.
  • Karyotype and Y-microdeletion testing are for selected men with azoospermia or severe oligozoospermia plus evidence of impaired sperm production.
  • In vasal agenesis or idiopathic obstructive azoospermia, test CFTR (including the 5T allele); if a mutation is found, offer the reproductive partner genetic evaluation and counselling.

Interpretation framework:

FindingFSHTestosteroneDiagnosisAction
Azoospermia + small testesHighLowPrimary testicular failureKaryotype + Y microdeletion
Azoospermia + normal testesNormalNormalObstructive patternExamine vasa/epididymides and semen volume/pH; directed CFTR/TRUS testing; consider reconstruction or retrieval
Oligospermia + low FSHLowLowHypogonadotrophic hypogonadismEstablish cause; pituitary imaging only when clinically indicated; specialist gonadotrophin/GnRH treatment
Any + high prolactinVariableLowHyperprolactinaemiaExclude physiological/drug/thyroid causes; image pituitary if persistently elevated and unexplained; treat the cause

Serum mid-luteal progesterone levels (a week before next expected period) [1]

For irregular cycles: FSH, prolactin, thyroxine, USS ovarian morphology (PCO) [1]

For regular cycles: prolactin or thyroxine NOT indicated [1]

Current first step: Menstrual history is usually enough: regular 21–35-day cycles generally do not need biochemical confirmation of ovulation. Use luteal progesterone when the history is indeterminate; if cycles are clearly irregular/absent, investigate the cause rather than merely “confirming” anovulation [13].

High Yield - Tests of Ovulation

Gold standard of ovulation is pregnancy. Other tests are inferential. Regular cycles (21–35 days) suggest 95% chance of ovulation. [1]

Serum progesterone: taken mid-luteal phase (~1 week before expected next period). > 3 ng/mL or > 10 nmol/L = presumptive evidence of recent ovulation. Levels fluctuate by sevenfold over a few hours. Not to assess quality of luteal phase. [1]

Why mid-luteal? Progesterone is secreted by the corpus luteum ONLY after ovulation. Its peak is approximately 7 days post-ovulation (= mid-luteal). If sampled too early or too late, you'll get a falsely low value. In a 28-day cycle, sample on day 21. In a 35-day cycle, sample on day 28.

Other Tests of Ovulation

TestHow It WorksLimitations
Basal Body Temperature (BBT)Progesterone causes ~0.3–0.5°F rise post-ovulation; BBT nadir suggests ovulationNot accurate: ovulation can occur 6 days before to 4 days after nadir. Difficult to interpret. Not useful for timing intercourse. [1]
Urinary LH kitsDetect LH surge ~24–36 hours before ovulation. Peak conception probability is the day before and day of ovulationUseful for timing intercourse; false negatives with dilute urine
Pelvic ultrasoundProgressive follicular growth → sudden collapse of pre-ovulatory follicle → internal echoes in corpus luteum → increase in cul-de-sac fluid [1]Labour intensive; requires repeated scanning [1]
Endometrial biopsySecretory changes confirm ovulationInvasive; NOT routinely recommended (ACOG 2019) [1]

The lecture's biphasic BBT graph is physiologically useful—progesterone raises temperature after ovulation—but BBT charts should not be used to confirm or precisely time ovulation because the thermal shift is retrospective and imprecise [13][20].

Hypothalamic: weight change (obesity, anorexia nervosa), drugs (tranquillizers), psychological disturbance [1]

Pituitary: tumours, Sheehan's syndrome, hyperprolactinaemia [1]

Ovary: ovarian insufficiency (chromosomal - Turner Syndrome, surgery, radiotherapy, chemotherapy, mumps), PCOS [1]

Other endocrine: thyroid disorders, adrenal disorders [1]

Investigation of Anovulation

The slide uses FSH > 25 IU/L as a pointer to ovarian insufficiency; a single result alone is not the diagnosis. [1]

Check prolactin for pituitary causes [1]

Check for PCOS (USS), thyroid (TFT), Cushing's [1]

From first principles: FSH is high in ovarian insufficiency because of the loss of negative feedback from oestradiol and inhibin B. The pituitary "shouts louder" (high FSH) trying to stimulate non-responsive ovaries. Conversely, in hypothalamic/pituitary causes, FSH is low or inappropriately normal despite low oestrogen.

Current POI criteria: In a person younger than 40, diagnose premature ovarian insufficiency from at least 4 months of amenorrhoea/irregular cycles plus biochemical confirmation with FSH > 25 IU/L; repeat FSH after 4–6 weeks if the diagnosis is uncertain [21].

Two main methods: Hysterosalpingogram (HSG) and Laparoscopy [1]

FeatureHSGLaparoscopy
InvasivenessLess invasive, outpatientOperative, requires GA
Uterine cavity assessmentCan assessLimited
AccuracyLower; false +ve due to proximal tubal spasmMore accurate
Peritubal adhesionsNot detectedCan visualize and treat
Endometriosis assessmentNoCan assess and treat
ComplicationsPain, vasovagal symptoms, contrast reaction and a small infection risk; assess infection risk locallyAnaesthetic and operative risks
When to useWomen with no comorbidities (no previous PID, ectopic, or clinical endometriosis)Women thought to have comorbidities

Hysterosalpingo-contrast-ultrasonography (HyCoSy) may be an alternative to HSG [1]

Hydrosalpinx (shown on lecture slides): A blocked, fluid-filled Fallopian tube. Important because hydrosalpinx fluid is embryotoxic and reduces IVF success rates. Current practice: salpingectomy or proximal tubal occlusion before IVF if hydrosalpinx is present.

Reading the Lecture Images

  • Normal HSG: contrast outlines the triangular uterine cavity, traverses thin tubes and disperses freely into both peritoneal cavities.
  • Proximal block/spasm: abrupt non-filling at the uterotubal junction; cornual spasm can mimic true occlusion, so interpret in clinical context.
  • Hydrosalpinx: a dilated, tortuous or club-ended contrast-filled tube with absent free spill, indicating distal occlusion.
  • What HSG cannot show well: external endometriotic implants and peritubal adhesions. The laparoscopic photographs show exactly these lesions—dark/red implants, endometriomas and fibrous bands tethering the tube or ovary—while chromopertubation demonstrates spill directly.

In the endometriosis ultrasound images, an endometrioma appears as a well-defined ovarian cyst with fairly homogeneous low-level “ground-glass” echoes. Bilateral endometriomas and adhesions can markedly distort tubo-ovarian anatomy.

Laparoscopy for unexplained infertility, advanced sperm function testing (DNA fragmentation), postcoital testing, thrombophilia testing, immunologic testing, karyotype, endometrial biopsy and prolactin — NOT routine without a specific indication. [1][13][14]

Exam Trap - What NOT to Order

Examiners love to test what you should NOT do. Post-coital test (PCT) was historically popular but has been abandoned — poor reproducibility and no correlation with pregnancy outcomes. Endometrial biopsy for "luteal phase defect" is also obsolete. Don't order karyotype unless indicated (testicular failure, recurrent miscarriage). Don't check prolactin in a woman with regular cycles.


6. Pre-Pregnancy Advice

0.4 mg folic acid whilst trying to conceive and during the first 12 weeks of pregnancy to prevent neural tube defects [1]

Reduce body weight in obese women [1]

Stop smoking, stop alcohol [1]

Stop smoking, avoid excessive alcohol [1]

Men with poor quality sperm advised to wear loose fitting underwear and trousers, and avoid occupational or social situations that might cause testicular hyperthermia [1]

Evidence qualifier: Avoiding sustained testicular heat is biologically plausible and low risk, but the evidence for most lifestyle/environmental interventions—including a specific underwear style—is limited. Do not present loose clothing as a proven fertility treatment [14].


7. Treatment

7.1 Ovulation Induction

Aim: development of a single follicle [1]

High Prolactin → Bromocriptine/Cabergoline Normal FSH + Anovulation (PCOS/Hypothalamic) → Optimize weight → Drugs → Surgery High FSH → Ovarian insufficiency → Donor eggs [1]

First-line oral therapy in PCOS. Aromatase inhibitor. 2.5–7.5 mg/day for 5 days. Ovulation and pregnancy rates higher than clomid. Less multiple pregnancy compared with clomid. [1]

Mechanism from first principles: Letrozole inhibits aromatase → blocks conversion of androgens to oestrogens → reduced oestrogen negative feedback on hypothalamus/pituitary → increased FSH secretion → follicular development. Because the aromatase inhibition is reversible and short-lived, typically only one dominant follicle develops (less risk of multiples vs clomid).

Anti-oestrogen acting at hypothalamus. 50–150 mg/day for 5 days; up to 6 cycles. Ovulation rate 50–80%. Pregnancy rate 30–50%. [1]

Side effects: hot flushes, multiple pregnancy, ovarian cysts, abdominal distension/pain, blurring of vision [1]

Mechanism: Clomiphene blocks oestrogen receptors at the hypothalamus → hypothalamus "thinks" oestrogen is low → increases GnRH → increases FSH/LH → follicular development. Unlike letrozole, clomiphene has a long half-life (5–7 days) and its anti-oestrogenic effect on cervical mucus and endometrium may paradoxically reduce pregnancy rates despite inducing ovulation.

Letrozole vs Clomiphene - Exam Discriminator

FeatureLetrozoleClomiphene
MechanismAromatase inhibitorAnti-oestrogen at hypothalamus
Current statusFirst-line for PCOSSecond-line
Ovulation/pregnancy rateHigherLower
Multiple pregnancy riskLowerHigher
Effect on endometriumNeutral/positiveAnti-oestrogenic (thin endometrium)
Effect on cervical mucusNeutralAnti-oestrogenic (hostile mucus)

FSH & LH or recombinant FSH injections. Acts directly on ovaries — very effective. Risk of OHSS and multiple pregnancy HIGH. Requires careful monitoring. [1]

The slide quotes multiple-pregnancy rates up to 40–50% and OHSS at 1–5%; these are historical, regimen-dependent figures, not current counselling estimates. [1]

The image of twins and triplets illustrates the key safety problem: uncontrolled multifollicular recruitment can produce iatrogenic multiple pregnancy. Modern low-dose regimens, ultrasound monitoring and cycle-cancellation thresholds aim for one mature follicle in ovulation induction and greatly reduce this risk [16][19].

OHSS explained from first principles: Excessive ovarian stimulation → multiple follicles develop → massive oestrogen and VEGF production → increased vascular permeability → third-space fluid shifts (ascites, pleural effusions) → haemoconcentration → thromboembolism risk. Severe OHSS can cause renal failure, ARDS, and death. This is why gonadotrophin therapy requires ultrasound monitoring and dose titration.

Clinical features of OHSS (from lecture slide) [1]: nausea, shortness of breath (± pleural effusion), abdominal fluid (ascites), and reduced urine output.

OHSS Red Flags

After fertility treatment, worsening abdominal pain/distension, persistent vomiting, reduced or dark urine, chest pain or breathlessness require urgent contact with the fertility unit or emergency assessment. Severe OHSS can cause haemoconcentration, thrombosis, renal impairment and pleural fluid [19].

The lecture reports ovulation > 90% and pregnancy 80% with bromocriptine; treat these as historical cohort estimates, not an individual prediction. Side effects include nausea and postural hypotension. [1]

Why it works: Prolactin inhibits GnRH → reduced FSH/LH → anovulation. By suppressing prolactin with a dopamine agonist, GnRH pulsatility is restored → normal ovulation resumes. Cabergoline (longer-acting, fewer side effects) is often preferred in practice but the lecture names bromocriptine.

Surgical option for PCOS [1]

Laparoscopic ovarian drilling uses diathermy to puncture the ovarian capsule at multiple points. This reduces androgen-producing stroma and often restores ovulatory cycles. It's a second-line option when medical therapy fails.

Metformin — an insulin-sensitising agent listed among ovulation induction drugs [1]

Metformin may be used as an adjunct in PCOS patients, particularly those with insulin resistance. It can improve ovulatory function and is sometimes combined with letrozole or clomiphene.

No intervention has been shown to reliably increase ovarian activity or natural conception in established POI, although intermittent spontaneous ovarian activity can occur. Donor-oocyte IVF uses a donor oocyte fertilized with partner or donor sperm, followed by embryo transfer to the recipient. [1][21]

This fertility statement does not mean “no medical care”: people with POI still require counselling, assessment of the cause and associated health risks, and appropriate hormone therapy for hypo-oestrogenism unless contraindicated [21].


Options: Tubal surgery vs IVF. Decision depends on: (1) The lesions, (2) The infertile couple, (3) The medical service [1]

Tubal surgery: microsurgical technique, laparotomy or laparoscopy. Types: adhesiolysis, re-anastomosis, salpingostomy [1]

When to choose surgery vs IVF:

  • Mild distal tubal disease → surgery may be reasonable (cumulative pregnancy rate over multiple cycles)
  • Severe tubal disease/bilateral hydrosalpinx → IVF preferred
  • Reversal of sterilization → surgery if ≥4 cm of healthy tube remains
  • Older woman or additional male factor → go straight to IVF

7.3 Male Factor Treatment

Potentially effective cause-directed treatments: selected varicocele repair, reconstruction of correctable obstruction, gonadotrophins/GnRH for hypogonadotrophic hypogonadism, and treatment of hyperprolactinaemia [1][15]

Varicocelectomy is considered when the varicocele is palpable, the couple is attempting conception and semen parameters are abnormal (except that evidence is uncertain in non-obstructive azoospermia). Do not operate on a non-palpable varicocele found only on imaging [15].

If medical treatment not applicable: Ovarian stimulation + IUI, or IVF with conventional insemination or ICSI [1]

Ejaculated sperm, Epididymal sperm (MESA — Microsurgical Epididymal Sperm Aspiration), Testicular sperm (TESE — Testicular Sperm Extraction) [1]

When to use each:

  • Ejaculated → first choice if any motile sperm present
  • MESA → obstructive azoospermia (e.g., CBAVD, failed vasectomy reversal)
  • TESE → non-obstructive azoospermia (may find focal spermatogenesis in testicular tissue)

The source diagram is an anatomical decision aid: ejaculated sperm are preferred when usable; epididymal retrieval (MESA/PESA) is primarily for obstruction, while testicular retrieval is used when epididymal sperm are unavailable or in selected non-obstructive azoospermia. All retrieved sperm require IVF with ICSI rather than IUI.

Anti-oestrogens, androgens, bromocriptine, and kinin-enhancing drugs for abnormal semen quality — NOT effective. Antioxidants, mast cell blockers, alpha-blockers need further evaluation. Systemic corticosteroids for antisperm antibodies — NOT recommended. [1]

Current nuance: selected SERMs, aromatase inhibitors or hCG may be used by specialists for infertile men with low endogenous testosterone, but benefits of empirical SERMs for idiopathic infertility are limited, and supplements/antioxidants have questionable clinical utility [15].

Exam Trap - Empirical Male Infertility Treatment

Do NOT recommend testosterone/androgens for male infertility with abnormal semen. Exogenous testosterone actually SUPPRESSES spermatogenesis via negative feedback on FSH/LH. This is a common misconception and exam trap.

Minimal/mild endometriosis: ovarian-suppression treatment does NOT enhance fertility. Operative laparoscopy, ovarian stimulation + IUI, and IVF are possible pathways. [1][22]

Current nuance: ESHRE strongly advises against ovarian suppression solely to improve fertility. Operative laparoscopy may be offered for rASRM stage I/II disease (weak recommendation); the decision should account for pain, age, ovarian reserve, prior surgery, other infertility factors and patient preference. Endometrioma surgery may reduce ovarian reserve, so “ablate all visible disease” is not an automatic rule [22].

Historical slide message: expectant management; no clomiphene alone or unstimulated IUI; IVF for persistent infertility. [1]

High Yield - Unexplained Infertility Management

Do not confuse unstimulated IUI with IUI plus ovarian stimulation. ESHRE 2023 recommends prognosis-guided treatment and regards stimulated IUI for 3–6 cycles as first-line for many couples; use low-dose stimulation and monitoring to limit multiple pregnancy/OHSS. IVF is individualized by age, duration, prior treatment and pregnancy history. ICSI is not routinely superior to conventional IVF when there is no male-factor indication [17].

Investigate cause and treat: psychotherapy, drugs for erectile dysfunction (e.g., Viagra). IUI by husband's sperm at time of ovulation. [1]

Sexual dysfunction and infertility overlap: Studies show 32.5% of subfertile women attending fertility clinics have sexual dysfunction [8]. Infrequent coitus → reduced exposure to sperm → infertility. Always ask about coital frequency and sexual function as part of fertility assessment.

Increases motile sperm in uterus through IUI around ovulation. Ovarian stimulation increases oocytes available. Pregnancy rate ~10% per cycle. [1]

How IUI works: Semen is washed and prepared (removing prostaglandins, debris and immotile sperm) → a thin transcervical catheter deposits concentrated motile sperm high in the uterine cavity around ovulation → sperm still travel through a Fallopian tube for in-vivo fertilization, so at least one functioning patent tube is generally required. If stimulation is used, oral agents or carefully monitored low-dose gonadotrophins may recruit additional follicles; excessive follicle recruitment should trigger cycle cancellation rather than accepting a high multiple-pregnancy risk [17].

7.8 In Vitro Fertilization (IVF)

1. Stimulation of ovaries, 2. Oocyte pickup, 3. Fertilization, 4. Embryo transfer [1]

Natural conception vs IVF diagram: Natural fertilization and early cleavage occur inside the Fallopian tube. IVF bypasses that tubal meeting point: follicles are stimulated, oocytes are aspirated with an ultrasound-guided transvaginal needle, fertilization and early cleavage occur in the laboratory, and a selected embryo is placed through the cervix into the uterine cavity. Implantation is still a biological event and is not guaranteed by transfer.

Period → Ovarian stimulation (FSH/hMG injections + GnRH agonist or antagonist to prevent premature LH surge) → hCG trigger injection → Egg retrieval → Embryo transfer → Pregnancy test [1]

Why suppress endogenous LH? Without suppression, the developing follicles could trigger a premature LH surge → premature ovulation → missed oocyte retrieval. GnRH agonists (after initial flare) or antagonists prevent this.

The timeline is schematic: protocols and trigger choice are individualized, and laboratory culture/fertilization plus luteal support occur between retrieval and pregnancy testing.

1. Conventional insemination: oocytes placed in culture medium with prepared sperm 2. Intracytoplasmic sperm injection (ICSI): injecting a single sperm directly into an oocyte [1]

When to use ICSI over conventional:

  • Severe male factor (very low count/motility)
  • Surgically retrieved sperm (MESA/TESE)
  • Previous fertilization failure with conventional IVF

ICSI does not routinely improve live birth over conventional IVF for unexplained or other non-male-factor infertility and adds manipulation, cost and laboratory work [17].

Day 0 (oocyte/insemination) → Day 1 (two-pronuclear fertilization check) → Day 2 (2–4 cells) → Day 3 (~8 cells) → Day 4 (compacting morula) → Day 5 (expanded blastocyst) → Day 6 (hatching blastocyst) [1]

The slide promotes single-embryo transfer but also shows an older local rule for transferring two embryos (age ≥38 or repeated failure). Treat that two-embryo rule as historical, not a current universal threshold. [1]

Single vs Double Embryo Transfer

The goal of ART is a healthy singleton. Elective single-embryo transfer is best practice for most people with a good-quality embryo; any decision to transfer more is individualized by embryo ploidy/stage and quality, age at oocyte collection, prognosis, previous outcomes, comorbidity and local regulation—not by the slide's age cut-off alone. A euploid embryo should be transferred singly regardless of age [18].

The lecture provides historical HKU-QMH outcome data from 2020–2021 [1]:

Fresh Embryo Transfer — Per-Transfer-Cycle Rates (2020–2021 approximate):

Female AgeClinical Pregnancy RateLive Birth Rate
< 36~32–33%~27–28%
36–40~28–32%~20–23%
> 40~8–14%~0–7%

Frozen Embryo Transfer (FET) — Per-Transfer-Cycle Rates (2020–2021 approximate):

Female AgeClinical Pregnancy RateLive Birth Rate
< 36~40–42%~33%
36–40~38–41%~28–29%
> 40~14–29%~8–23%

Cumulative Live Birth Rate — First IVF Cycle (HKU-QMH data):

Age GroupCumulative Live Birth Rate
≤ 30~66%
31–35~58–60%
36–40~46–50%
> 40~11–14%

How to interpret the charts:

  • The consistent visual signal is the decline with female age, especially above 40; age is the strongest predictor of treatment success.
  • Clinical-pregnancy rate is higher than live-birth rate because not every clinical pregnancy results in a live birth.
  • A frozen-transfer bar that is higher than a fresh-transfer bar does not prove frozen transfer is intrinsically superior: these are per-transfer, selected groups with different denominators and case mix.
  • Cumulative live birth from all usable embryos generated in one retrieval is more meaningful for counselling than a single transfer's pregnancy rate. In the local 2013–2020 cohorts shown, cumulative live birth was about 58–67% at age ≤35, 46–50% at 36–40 and 11–14% above 40; these are historical centre-specific estimates, not promises of current individual outcome.

1. Age of women is an important factor. Older women should be investigated and treated early. [1]

2. Three most important investigations: Semen analysis, Serum progesterone, HSG and/or laparoscopy [1]

3. Effective treatment should be offered for long-standing infertility [1]

Current correction to point 2: The principle is to evaluate semen, ovulation and the female reproductive tract—but not with a fixed three-test bundle. Regular 21–35-day cycles usually establish an ovulatory pattern without progesterone, HSG/HyCoSy are first-line tubal tests, and laparoscopy is reserved for suspected pelvic pathology or another operative indication [13].


The 2020 SAQ tested surrogacy ethics [9]:

  • Gestational surrogacy (embryo implanted in surrogate who has no genetic relationship) vs traditional surrogacy (surrogate's own oocyte)
  • Ethical challenges: commodification of reproduction, exploitation of surrogates, legal parentage, psychological impact on surrogate/child, consent issues
  • Arguments supporting: reproductive autonomy, fulfilling desire for genetically related child

The 2022 SAQ tested oocyte freezing and donor sperm ethics [10]:

  • Storage duration of oocytes in HK: 10 years (extendable under certain conditions)
  • Ethical concerns: welfare of the unborn child, social vs medical egg freezing, single parenthood
  • Donor sperm ethical objections: anonymity issues, commodification, welfare of child, right to know genetic origin

Hyperprolactinaemia [3][4][7]: Prolactin inhibits GnRH → hypogonadotrophic hypogonadism → anovulation in women, impotence/infertility in men. Causes include prolactinoma, drugs (antipsychotics, antiemetics), hypothyroidism (↑TRH). Treatment: dopamine agonists (bromocriptine, cabergoline).

Turner Syndrome (45,X) [6]: Ovarian dysgenesis → primary ovarian insufficiency → high FSH, streak gonads. Pregnancy only possible with donor oocyte IVF.

Klinefelter Syndrome (47,XXY) [3]: Small firm testes, azoospermia, tall stature, gynaecomastia. High FSH, low testosterone. Micro-TESE may rarely retrieve sperm for ICSI.

Chlamydia trachomatis is the most common bacterial cause of PID → tubal damage → infertility, ectopic pregnancy [11][12]. Gonorrhoea can also cause PID and infertility. This is why previous STD history is a red flag for tubal factor infertility and warrants laparoscopy over HSG.

High Yield Summary

  1. Definition

    • Infertility evaluation begins after 12 months of regular unprotected intercourse if the female partner is < 35, after 6 months if ≥35, and sooner for known risk factors or age > 40. Infertility affects 10–15% of couples.
  2. Five causes

    • Ovulatory dysfunction, tubal factors, endometriosis, male factors, unexplained.
  3. Three assessment domains

    • Assess (1) semen, (2) ovulatory status, and (3) female tract structure/patency. Start with at least one semen analysis and repeat if abnormal; menstrual history often establishes ovulation; use HSG/HyCoSy for tubal patency and reserve laparoscopy for a specific indication.
  4. Ovulation induction

    • Letrozole (1st line for PCOS) > Clomiphene > Gonadotrophins > Ovarian drilling. Bromocriptine for hyperprolactinaemia. Donor oocytes for ovarian insufficiency.
  5. Male factor

    • Gonadotrophins for hypogonadotrophic hypogonadism; vasectomy reversal for obstruction; IUI or IVF/ICSI for most cases. NEVER give testosterone for oligospermia.
  6. Unexplained infertility

    • Clomiphene alone and unstimulated IUI are not useful; prognosis-guided ovarian stimulation + IUI is first-line for many couples, with IVF individualized.
  7. IVF

    • Ovarian stimulation → transvaginal oocyte retrieval → conventional insemination or indicated ICSI → embryo culture → embryo transfer. Aim for a healthy singleton; embryo number is individualized, not dictated by the slide's old ≥38/failed-cycle rule.
  8. Pre-pregnancy

    • Folic acid 0.4 mg, weight optimization, stop smoking/alcohol, and avoid sustained testicular heat; evidence for a specific underwear style is limited.
  9. Age is the single most important prognostic factor.

    • Start evaluation at 6 months if ≥35 and consider immediate evaluation above 40.

Active Recall - Infertility

[1] Lecture slides: GC 117. I want to have a baby male and female infertility.pdf (all pages) [2] Lecture slides: Block C - I want to have a baby_ male and female infertility.pdf (p1) [3] Senior notes: Block A - I keep on bumping into people on my side_ pituitary tumours; hypopituitarism.pdf (p21-22) [4] Senior notes: Ryan Ho Endocrine.pdf (p110) [5] Senior notes: Adrian Lui Pediatrics Notes.pdf (p182) — CF and absent vas deferens [6] Senior notes: Adrian Lui Pediatrics Notes.pdf (p506) — Turner Syndrome [7] Senior notes: Ryan Ho Fundamentals.pdf (p443) [8] Lecture slides: MBBS_SRH_2025.8.10.pdf (p35) — Sexual dysfunction in subfertile women [9] Past papers: 2020 Fourth Summative SAQ.pdf (Q12) — Surrogacy ethics [10] Past papers: 2022 Fourth Summative SAQ.pdf (Q10) — Oocyte freezing and donor sperm [11] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (p1052) — Chlamydia and PID [12] Senior notes: Ryan Ho Urogenital.pdf (p241, p249) — STDs and infertility [13] ASRM Practice Committee. Fertility evaluation of infertile women (2021) [14] AUA/ASRM. Diagnosis and treatment of infertility in men, Part I [15] AUA/ASRM. Diagnosis and treatment of infertility in men, Part II [16] International PCOS Guideline Group. Recommendations from the 2023 international evidence-based PCOS guideline [17] ESHRE. Unexplained infertility guideline (2023) [18] ASRM/SART. Guidance on limits to the number of embryos to transfer (2021) [19] RCOG. Management of ovarian hyperstimulation syndrome, Green-top Guideline No. 5 (2026) [20] NICE. Fertility problems: assessment and treatment, NG257 (2026) [21] International POI Guideline Group. Evidence-based guideline: premature ovarian insufficiency (2024/2025) [22] ESHRE. Guideline: Endometriosis (2022)

On this page

No Headings